Unreported / Non-Citable
Background
Two former insiders brought a False Claims Act case alleging that Regeneron and related companies used speaker fees, travel, meals, and other physician payments to induce prescriptions paid by federal healthcare programs. Public datasets already disclosed that payments occurred, but the relators alleged nonpublic details about internal compensation exceptions, return-on-investment scorecards, sham educational events, and payments above fair market value.
The Central District of California dismissed the complaint, applying the False Claims Act’s public-disclosure bar and rejecting other theories. The relators appealed. The Ninth Circuit’s unpublished memorandum addressed whether public payment data already revealed substantially the same fraud and whether the complaint described an Anti-Kickback Statute violation with sufficient specificity.
The Court’s Holding
The panel held that the public-disclosure bar did not defeat the Regeneron claims. Public data showed transactions, but not the alleged fraudulent substructure or intent. The insiders supplied the missing details: unjustified departures from internal fair-market-value tiers, audits questioning compensation, scorecards tied to prescribing, withdrawal of support when a doctor’s prescriptions fell, luxury benefits, and events allegedly paid for but never held. Those facts added more than a publicly visible piece of the puzzle.
The majority also concluded that the allegations plausibly described remuneration intended to exert undue influence over referrals and met fraud pleading standards. The Anti-Kickback Statute can apply when inducing referrals is one purpose of a payment even if the payment also compensates legitimate services. The panel therefore reversed or vacated significant portions of the dismissal and remanded, while affirming other rulings.
Judge Lee dissented in part, reasoning that correlation between payments and prescriptions did not establish causation and that several internal allegations remained too vague. In his view, policy exceptions and generous benefits did not by themselves show the undue influence required by the statute.
Key Takeaways
- Public physician-payment data do not automatically trigger the False Claims Act’s public-disclosure bar when insiders add material details about the alleged scheme.
- Internal audits, compensation exceptions, prescription scorecards, and payments for nonexistent events can supply particularized indicia of fraudulent intent.
- An Anti-Kickback claim may proceed when inducement is one purpose of a payment, even if legitimate services are also involved.
- Healthcare defendants should test each allegation for the who, what, when, where, and how required by Rule 9(b).
- The memorandum is nonprecedential but illustrates how the Ninth Circuit applies recent kickback and disclosure-bar doctrine.
Why It Matters
For California healthcare companies and whistleblower counsel, the case shows the dividing line between repackaging public payment data and contributing genuinely valuable insider knowledge. Detailed operational facts can keep a case alive even when the government could already see the underlying transactions.
Compliance teams should treat undocumented fair-market-value overrides, hospitality exceptions, and event verification as litigation risks. A written policy helps only if practices and approvals match it.